Dr Dulcy Mitchell, OD in N Kingstown, RI - Optometrist

Dr Dulcy Mitchell, OD is a Optometrist based in N Kingstown, Rhode Island. Dr Dulcy Mitchell is licensed to practice in Rhode Island (license number ODTG00565) and her current practice location is 7805 Post Rd, N Kingstown, Rhode Island. She can be reached at her office (for appointments etc.) via phone at (401) 294-1010.

NPI number for Dr Dulcy Mitchell is 1376811448 and her current mailing address is 566 Toll Gate Rd, Warwick, Rhode Island. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1376811448.

Contact Information

	Dr Dulcy Mitchell, OD
	7805 Post Rd, N Kingstown, RI 02852-4405
	(401) 294-1010
	(401) 295-2050

Healthcare Provider's Profile

Full Name	Dr Dulcy Mitchell
Gender	Female
Speciality	Optometrist
Location	7805 Post Rd, N Kingstown, Rhode Island
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1376811448
Provider Enumeration Date: 12/05/2011
Last Update Date: 10/30/2013

Medical Identifiers

Medical identifiers for Dr Dulcy Mitchell such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1376811448	NPI	-	NPPES
DM87167	Medicaid	RI

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	ODTG00565 (Rhode Island)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Dulcy Mitchell is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Dulcy Mitchell, OD 566 Toll Gate Rd, Warwick, RI 02886-2716 Ph: (401) 738-4800	Dr Dulcy Mitchell, OD 7805 Post Rd, N Kingstown, RI 02852-4405 Ph: (401) 294-1010

News Archive

Bacteria that cause gum disease also promote heart disease, shows study

A University of Florida study shows that the same bacteria that cause gum disease also promotes heart disease - a discovery that could change the way heart disease is diagnosed and treated. Researchers report their findings today at the annual meeting of the American Society for Microbiology.

Does the brain thin as children grow?

Neuroscientists have long held that the brains of children thin down over time. However, this was on the basis of older imaging techniques. Now, using cutting-edge technology in the form of quantitative magnetic resonance imaging (qMRI), a team of researchers has found that the apparent thinning is due in part to myelin formation around the cortical nerve fibers. These very interesting findings, published in the journal PNAS on September 23, 2019, will drive further research on the link between cortical function and structure.

KYTHERA commences two ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the initiation of two pivotal U.S. Phase III trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental (under the chin) fat.

Clinical trial to test efficacy of new drug for chronic cough

The National Institute for Health Research has today announced its participation in a clinical trial to test a promising new treatment for chronic cough. If approved, this would be the first new cough drug in 50 years and offer hope to the millions of people living with chronic cough for whom few, if any, effective treatments exist.

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Boehringer Ingelheim announced today that the European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA®. It will be indicated in adults whose blood pressure is not adequately controlled on amlodipine and is also indicated as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of TWYNSTA containing the same component doses.

Dr Dulcy Mitchell, OD - Optometrist in N Kingstown, RI